These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 19221265)

  • 21. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review.
    Sanyal S; Marckmann P; Scherer S; Abraham JL
    Nephrol Dial Transplant; 2011 Nov; 26(11):3616-26. PubMed ID: 21441397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transglutaminases: the missing link in nephrogenic systemic fibrosis.
    Parsons AC; Yosipovitch G; Sheehan DJ; Sangüeza OP; Greenberg CS; Sane DC
    Am J Dermatopathol; 2007 Oct; 29(5):433-6. PubMed ID: 17890909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A; Witzke O; Hillen U; Barkhausen J; Daul AE; Erbel R
    J Am Coll Cardiol; 2009 May; 53(18):1621-8. PubMed ID: 19406336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Nephrogenic systemic fibrosis].
    Adar T; Rubinger D; Lalazar G; Levi L; Mizrahi M; Bogot RN
    Harefuah; 2008 Oct; 147(10):801-3, 837. PubMed ID: 19039911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor.
    Moreno-Romero JA; Segura S; Mascaró JM; Cowper SE; Julià M; Poch E; Botey A; Herrero C
    Br J Dermatol; 2007 Oct; 157(4):783-7. PubMed ID: 17627792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
    Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
    Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nephrogenic systemic fibrosis: clinical picture and treatment.
    Marckmann P; Skov L
    Radiol Clin North Am; 2009 Sep; 47(5):833-40, vi. PubMed ID: 19744598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats.
    Pietsch H; Raschke M; Ellinger-Ziegelbauer H; Jost G; Walter J; Frenzel T; Lenhard D; Hütter J; Sieber MA
    Invest Radiol; 2011 Jan; 46(1):48-56. PubMed ID: 20938346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature.
    Mathur K; Morris S; Deighan C; Green R; Douglas KW
    J Clin Apher; 2008; 23(4):144-50. PubMed ID: 18633995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Findings of osseous sclerotic bodies: a unique sequence of cutaneous bone formation in nephrogenic systemic fibrosis.
    Kartono F; Basile A; Roshdieh B; Schwimer C; Shitabata PK
    J Cutan Pathol; 2011 Mar; 38(3):286-9. PubMed ID: 20726931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors.
    Bahrami S; Raman SS; Sauk S; Salehmoghaddam S; Villablanca JP; Finn JP; Lu DS
    J Comput Assist Tomogr; 2009; 33(6):819-23. PubMed ID: 19940643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis in 2 patients with end-stage renal disease on hemodialysis.
    Kim RH; Ma L; Hayat SQ; Ahmed MM
    J Clin Rheumatol; 2006 Jun; 12(3):134-6. PubMed ID: 16755242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alefacept therapy for nephrogenic systemic fibrosis: a case series.
    Robinson MR; Routhouska SB; Paspulati RM; Korman NJ
    J Drugs Dermatol; 2011 Aug; 10(8):922-4. PubMed ID: 21818517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Feb; 56(7):137-41. PubMed ID: 17318112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Nephrogenic systemic fibrosis--new clinical entity].
    Prvulović M
    Med Pregl; 2008; 61(9-10):439-41. PubMed ID: 19203058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure.
    Todd DJ; Kagan A; Chibnik LB; Kay J
    Arthritis Rheum; 2007 Oct; 56(10):3433-41. PubMed ID: 17907148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase.
    Swaminathan S; Arbiser JL; Hiatt KM; High W; Abul-Ezz S; Horn TD; Shah SV
    J Am Acad Dermatol; 2010 Feb; 62(2):343-5. PubMed ID: 20115955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
    Grobner T
    Nephrol Dial Transplant; 2006 Apr; 21(4):1104-8. PubMed ID: 16431890
    [No Abstract]   [Full Text] [Related]  

  • 40. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.